Top ▲

Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family C

Formerly known as: VEGF (vascular endothelial growth factor) receptor family

Unless otherwise stated all data on this page refer to the human proteins. Gene information is provided for human (Hs), mouse (Mm) and rat (Rn).


« Hide

VEGF receptors are homo- and heterodimeric proteins, which are characterized by seven Ig-like loops in their extracellular domains and a split kinase domain in the cytoplasmic region. They are key regulators of angiogenesis and lymphangiogenesis; as such, they have been the focus of drug discovery for conditions such as metastatic cancer. Splice variants of VEGFR1 and VEGFR2 generate truncated proteins limited to the extracellular domains, capable of homodimerisation and binding VEGF ligands as a soluble, non-signalling entity. Ligands at VEGF receptors are typically homodimeric. VEGFA (VEGFA, P15692) is able to activate VEGFR1 homodimers, VEGFR1/2 heterodimers and VEGFR2/3 heterodimers. VEGFB (VEGFB, P49765) and placental growth factor (PGF, P49763) activate VEGFR1 homodimers, while VEGFC (VEGFC, P49767) and VEGFD (VEGFD, O43915) activate VEGFR2/3 heterodimers and VEGFR3 homodimers, and, following proteolysis, VEGFR2 homodimers.


VEGFR-1 (fms related receptor tyrosine kinase 1) C Show summary » More detailed page

VEGFR-2 (kinase insert domain receptor) C Show summary » More detailed page

VEGFR-3 (fms related receptor tyrosine kinase 4) C Show summary » More detailed page


Show »


Show »

How to cite this family page

Database page citation:

Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family. Accessed on 24/10/2020. IUPHAR/BPS Guide to PHARMACOLOGY,

Concise Guide to PHARMACOLOGY citation:

Alexander SPH, Fabbro D, Kelly E, Mathie A, Peters JA, Veale EL, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators. (2019) The Concise Guide to PHARMACOLOGY 2019/20: Catalytic receptors. Br J Pharmacol. 176 Suppl 1: S247-S296.